Table 3.
Associations of soy isoflavones intake with osteoporotic fracture by any bone fracture history among postmenopausal women
| Adj. HR (95 % CI)a | P for interactionb | |||
|---|---|---|---|---|
| Overall | With BF history | Without BF history | ||
| Soy isoflavone intake (mg/d) | ||||
| <18⋅7 | 1⋅00 (ref.) | 1⋅00 (ref.) | 1⋅00 (ref) | |
| 18⋅7–29⋅0 | 1⋅08 (0⋅95–1⋅22) | 1⋅07 (0⋅87–1⋅31) | 1⋅08 (0⋅92–1⋅27) | 0⋅002 |
| 29⋅1–42⋅0 | 1⋅02 (0⋅89–1⋅16) | 0⋅84 (0⋅67–1⋅05) | 1⋅13 (0⋅95–.34) | |
| >42⋅0 | 1⋅01 (0⋅86–1⋅18) | 0⋅72 (0⋅55–0⋅93) | 1⋅22 (1⋅01–1⋅48) | |
| Daidzein intake (mg/d) | ||||
| <7⋅7 | 1⋅00 (ref.) | 1⋅00 (ref.) | 1⋅00 (ref.) | |
| 7⋅7–12⋅0 | 1⋅06 (0⋅93–1⋅20) | 1⋅05 (0⋅86–1⋅29) | 1⋅07 (0⋅91–1⋅25) | 0⋅004 |
| 12⋅17⋅6 | 1⋅00 (0⋅87–1⋅14) | 0⋅83 (0⋅66–1⋅04) | 1⋅11 (0⋅93–1⋅31) | |
| >17⋅6 | 1⋅02 (0⋅88–1⋅19) | 0⋅75 (0⋅58–0⋅97) | 1⋅21 (1⋅00–1⋅47) | |
| Genistein intake (mg/d) | ||||
| <10⋅6 | 1⋅00 (ref.) | 1⋅00 (ref.) | 1⋅00 (ref.) | |
| 10⋅6–16⋅6 | 1⋅05 (0⋅92–1⋅19) | 1⋅03 (0⋅84–1⋅27) | 1⋅06 (0⋅90–1⋅24) | 0⋅004 |
| 16⋅7–24⋅2 | 1⋅00 (0⋅88–1⋅15) | 0⋅83 (0⋅67–1⋅04) | 1⋅11 (0⋅94–1⋅31) | |
| >24⋅2 | 1⋅03 (0⋅89–1⋅20) | 0⋅76 (0⋅59–0⋅98) | 1⋅22 (1⋅01–1⋅48) | |
| Glycitein intake (mg/d) | ||||
| <1⋅6 | 1⋅00 (ref.) | 1⋅00 (ref.) | 1⋅00 (ref.) | |
| 1⋅6–2⋅4 | 1⋅11 (0⋅98–1⋅25) | 1⋅05 (0⋅86–1⋅29) | 1⋅14 (0⋅97–1⋅34) | 0⋅02 |
| 2⋅5–3⋅4 | 1⋅03 (0⋅90–1⋅19) | 0⋅89 (0⋅71–1⋅12) | 1⋅12 (0⋅95–1⋅34) | |
| >3⋅4 | 1⋅03 (0⋅87–1⋅21) | 0⋅77 (0⋅59–1⋅01) | 1⋅21 (0⋅99–1⋅49) | |
a
Adjusting for: Age, BF history, income, educational level, cigarette smoking status, alcohol consumption, regular exercise, BMI, Charlson's Score, breasting time, calcium supplement use, daily dietary intake of calories, vitamin D, calcium and magnesium.
b
P-value for interaction between soy isoflavones and BF history.